Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

11.39
+0.64005.95%
Post-market: 11.390.00000.00%19:51 EDT
Volume:532.80K
Turnover:6.19M
Market Cap:614.88M
PE:-1.91
High:12.11
Open:10.87
Low:10.75
Close:10.75
52wk High:17.40
52wk Low:7.90
Shares:53.98M
Float Shares:17.65M
Volume Ratio:0.71
T/O Rate:3.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.9500
EPS(LYR):-115.2900
ROE:-125.02%
ROA:-36.19%
PB:1.32
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
Eikon Therapeutics
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
384
Office Location:
230 Harriet Tubman Way,Millbrae,California,United States
Zip Code:
94030
Fax:
- -
Introduction:
Eikon Therapeutics, Inc. was incorporated in Delaware on July 9, 2019. It is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, primarily in oncology. The leadership team has a notable track record of successfully developing impactful drugs. The company's strategy leverages a proprietary technology platform to create novel therapies, with lead candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.

Directors

Name
Position
Roger M. Perlmutter
Chair and Chief Executive Officer and Director
David Meline
Director
Joshua Wolfe
Director
Kenneth C. Frazier
Director
Leon Chen
Director
Robert Huffines
Director

Shareholders

Name
Position
Roger M. Perlmutter
Chair and Chief Executive Officer and Director
Michael Klobuchar
Chief Operating Officer
Alfred Bowie
Chief Financial Officer
Benjamin Thorner
Chief Business Officer and General Counsel
Roy Baynes
Chief Medical Officer